(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of -48.14% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.59%.
Foghorn Therapeutics's revenue in 2026 is $36,739,000.On average, 11 Wall Street analysts forecast FHTX's revenue for 2026 to be $1,802,344,310, with the lowest FHTX revenue forecast at $1,123,213,848, and the highest FHTX revenue forecast at $2,761,714,074. On average, 11 Wall Street analysts forecast FHTX's revenue for 2027 to be $438,382,395, with the lowest FHTX revenue forecast at $0, and the highest FHTX revenue forecast at $3,111,493,579.
In 2028, FHTX is forecast to generate $604,898,819 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,111,909,277.